GSK2118436A |
DABRAFENIB |
TAFINLAR |
GSK-2118436A |
GSK-2118436 |
GSK2118436 |
TAFINLAR® |
DRB436 |
rxcui:1424911 |
pubchem.compound:44462760 |
drugbank:08912 |
chemidplus:1195765-45-7 |
chembl:CHEMBL2028663 |
Pharmaceutical Developer | GlaxoSmithKline |
Source Reported Drug Name(s) | Dabrafenib/GSK2118436 |
Drug Class | RAF Inhibitor |
FDA Approval | Melanoma (with BRAF V600 mutation) |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
Drug Categories | proto-oncogene proteins b-raf, antagonists & inhibitors |
Drug Categories | protein kinase inhibitors |
Drug Groups | investigational |
Drug Categories | breast cancer resistance protein inhibitors |
Drug Categories | cytochrome p-450 cyp2b6 inducers |
Drug Categories | cytochrome p-450 cyp2b6 inducers (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c19 inducers |
Drug Categories | cytochrome p-450 cyp2c8 inducers |
Drug Categories | cytochrome p-450 cyp2c8 inducers (weak) |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (strong) |
Drug Categories | cytochrome p-450 cyp2c8 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp2c9 inducers |
Drug Categories | cytochrome p-450 cyp2c9 inducers (strong) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inducers |
Drug Categories | cytochrome p-450 cyp3a4 inducers (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | drugs causing inadvertant photosensitivity |
Drug Categories | kinase inhibitor |
Drug Categories | oat1/slc22a6 inhibitors |
Drug Categories | oat3/slc22a8 inhibitors |
Drug Categories | oatp1b1/slco1b1 inhibitors |
Drug Categories | oatp1b3 inhibitors |
Drug Categories | organic anion transporter 1 inhibitors |
Drug Categories | organic anion transporting polypeptide 1b1 inhibitors |
Drug Categories | organic anion transporting polypeptide 1b3 inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
Drug Categories | photosensitizing agents |
Drug Categories | potential qtc-prolonging agents |
Drug Categories | qtc prolonging agents |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Response Type | predicted – resistant |
Indication/Tumor Type | ovarian cancer |
combination therapy | AMG 232 + Trametinib + Dabrafenib |
antagonist (inhibitory) |
inhibitor (inhibitory) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
DABRAFENIB | DrugBank Drug Name |
1195765-45-7 | CAS Number |
Tafinlar | Drug Brand |
Drug Groups | approved |
Drug Type | small molecule |
Drug Groups | investigational |
44462760 | PubChem Drug ID |
Dabrafenib | Drug Trade Name |
Dabrafenib | Drug Development Name |
Drug Class | RAF Inhibitor |
Source Reported Drug Name(s) | Dabrafenib/GSK2118436 |
Pharmaceutical Developer | GlaxoSmithKline |
DABRAFENIB | Generic Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Melanoma (with BRAF V600 mutation) |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
DABRAFENIB | Primary Drug Name |
DABRAFENIB | Drug Generic Name |
TAFINLAR | Drug Trade Name |
D05ROI | TTD Drug ID |
DABRAFENIB | GuideToPharmacology Ligand Name |